Speak directly to the analyst to clarify any post sales queries you may have.
The global blood and plasma components market is evolving rapidly, presenting both challenge and opportunity for senior stakeholders focused on advancing healthcare solutions and maintaining organizational resilience. This sector’s progress is driven by expanding clinical demands, innovation, and a growing need for reliable therapies across diverse patient populations.
Market Snapshot: Blood and Plasma Components Market
The blood and plasma components market experienced notable growth, increasing from USD 45.86 billion in 2024 to USD 48.62 billion in 2025. Projections indicate the market will reach USD 72.55 billion by 2032, with a compound annual growth rate (CAGR) of 5.90%. Expansion is fueled by broadening therapeutic use, continuous innovation in component processing, and rising demand for essential plasma-derived proteins. Wider clinical adoption, especially in emerging and advanced economies, combined with an industry-wide push for improved patient care, sustains an optimistic market outlook.
Scope & Segmentation
This comprehensive report offers decision-makers an in-depth analysis of the blood and plasma components market, highlighting opportunities and complexities across the global supply chain. The following key segments are covered:
- Product Types: Platelets, red blood cells, white blood cells, and plasma proteins including albumin, coagulation factors such as Factor IX, Factor VIII, prothrombin complex concentrates, as well as immunoglobulins for both intravenous and subcutaneous use.
- Applications: Diagnostic usage, research initiatives aimed at medical advances, and therapeutic interventions addressing various clinical needs.
- End Users: Diagnostic laboratories, hospitals (spanning ambulatory surgical centers, government and private hospitals), and research institutions engaged in both clinical practice and innovation.
- Distribution Channels: Hospital pharmacies prioritized for urgent care, online pharmacies supporting expanded access, and retail pharmacies ensuring routine availability.
- Geographic Coverage: In-depth insights span the Americas (including the United States, Canada, and key Latin American countries), Europe (covering the United Kingdom, Germany, France, and significant regional markets), the Middle East and Africa (with markets such as the UAE, Saudi Arabia, and South Africa), and Asia-Pacific (notably China, India, Japan, and several rapidly developing markets).
- Company Profiles: Industry leaders such as CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Biotest AG, KEDRION S.p.A., Shanghai RAAS Blood Products Co., Ltd, Bio Products Laboratory Limited, LFB S.A., and Sanquin Blood Supply Foundation.
Key Takeaways
- Technological innovation in blood fractionation and purification is enhancing the efficiency and safety of plasma-derived therapeutics, helping organizations respond to evolving therapeutic requirements.
- The shift towards automated systems and digital monitoring platforms is improving traceability while strengthening the integrity of production and distribution processes within the market.
- Consolidation through mergers and acquisitions is reshaping the competitive landscape, leading to diversified product portfolios and stronger security over supply chains.
- Rising interest in personalized medicine is increasing demand for advanced plasma-based treatments, notably immunoglobulin therapies that address complex autoimmune and neurological diseases.
- Compliance with emerging regulations is driving sustained investment in quality control and workforce training, further elevating standards and increasing barriers to entry.
- Distinct regional dynamics continue to influence growth potential, with mature infrastructure supporting North America, varied regulatory responses in Europe and the Middle East & Africa, and intensified healthcare modernization accelerating expansion in Asia-Pacific.
Tariff Impact: Navigating Regulatory and Economic Shifts
Ongoing regulatory measures, including proposed tariffs in the United States, are creating new cost dynamics and prompting organizations to re-align supply chain strategies. Industry stakeholders are responding by investing in domestic manufacturing capabilities and establishing long-term procurement partnerships to ensure continuous access to blood and plasma-derived products. These adaptive strategies help minimize supply disruptions and protect patient care delivery amid shifting policy environments.
Methodology & Data Sources
This report synthesizes primary insights from clinician, procurement, and laboratory manager interviews with in-depth secondary research, including regulatory documentation, clinical trial outcomes, and corporate reports. Validation was achieved through targeted industry surveys and review by interdisciplinary experts, ensuring comprehensive and relevant findings.
Why This Report Matters
- Empowers executive teams to manage regulatory and tariff-driven risks with targeted, actionable insights.
- Provides guidance for investing in automation and digital initiatives that boost traceability, adaptability, and market positioning across all geographic regions.
- Supports timely identification of growth areas within clinical and diagnostic segments, optimizing strategic direction and resource allocation.
Conclusion
Leveraging data-driven strategies remains crucial for navigating the evolving clinical and regulatory environment of the blood and plasma components market. Informed decision-making strengthens both business and clinical outcomes, positioning organizations at the forefront of healthcare advancement.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
Samples
LOADING...
Companies Mentioned
The key companies profiled in this Blood & Plasma Components market report include:- CSL Limited
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Biotest AG
- KEDRION S.p.A.
- Shanghai RAAS Blood Products Co., Ltd
- Bio Products Laboratory Limited
- LFB S.A.
- Sanquin Blood Supply Foundation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 183 |
Published | October 2025 |
Forecast Period | 2025 - 2032 |
Estimated Market Value ( USD | $ 48.62 Billion |
Forecasted Market Value ( USD | $ 72.55 Billion |
Compound Annual Growth Rate | 5.9% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |